Share this video  

BTOG 2017 | How to discuss immunotherapy as a treatment option with lung cancer patients

Rolf A. Stahel, MD, University Hospital Zürich, Zürich, Switzerland, provides advice on how to discuss immunotherapy as a second-line treatment option for patients with lung cancer. He highlights that approximately 1in 6 to 1 in 5 patients benefit from the treatment and that this should be clearly communicated to patients.

Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.